Skip to main content

Breast cancer

14-03-2018 | Breast cancer | News | Article

ACE inhibitors, beta blockers may protect against anthracycline-associated cardiotoxicity

The results of two independent trials suggest a role for the prophylactic use of angiotensin converting enzyme inhibitors or beta blockers in patients receiving an anthracycline-based regimen for HER2-positive or HER2-negative breast cancer.


ACC 2018; Orlando, Florida, USA, J Am Coll Cardiol 2018; Advance online publication

09-03-2018 | Breast cancer | News | Article

News in brief

US breast cancer screening guidelines questioned for ethnic minority women

An analysis of the Surveillance, Epidemiology, and End Results database has found racial differences in age at breast cancer diagnosis, indicating that the current age-based US Preventive Services Task Force guidelines may lead to underscreening in women of ethnic minorities.

08-03-2018 | Breast cancer | News | Article

Upfront aromatase inhibition as good as switch strategy in early breast cancer

The efficacy of aromatase inhibition is comparable regardless of whether the agents are taken upfront for 5 years or for 3 years following 2 years of tamoxifen in postmenopausal women with hormone receptor-positive, early-stage breast cancer, researchers report.


Lancet Oncol 2018; Advance online publication

05-03-2018 | Breast cancer | News | Article

News in brief

Adding metronomic chemotherapy to dual HER2-blockade may benefit older breast cancer patients

Older women with metastatic, HER2-positive breast cancer derive a progression-free survival benefit from the addition of metronomic chemotherapy to the anti-HER2 agents pertuzumab and trastuzumab, indicate results from the EORTC 75111-10114 trial.

02-03-2018 | Breast cancer | News | Article

In other news: Breast cancer focus

Here we provide top-line summaries of results from three phase III breast cancer trials, evaluating nab-paclitaxel and a trastuzumab biosimilar in the nonmetastatic HER2-negative and -positive settings, respectively, and quality of life with the addition of palbociclib in the advanced or metastatic setting.

01-03-2018 | Breast cancer | News | Article

Adjuvant chemotherapy benefit for ER-negative isolated local breast cancer recurrences confirmed

The final analysis of the CALOR trial confirms the disease-free survival benefit of adjuvant chemotherapy for breast cancer patients with resected isolated locoregional recurrences that are estrogen receptor-negative and rules out its use in the ER-positive scenario.


J Clin Oncol 2018; Advance online publication

image credits